Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Anita Dushyanth is an analyst at Berenberg. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/29/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/27/2022 | SERA | Buy Now | Sera Prognostics | $3.50 | 271.43% | Anita Dushyanth61% | → $13 | Initiates | → Buy | Get Alert |
| 04/27/2022 | URGN | Buy Now | UroGen Pharma | $11.20 | 78.57% | Anita Dushyanth61% | → $20 | Initiates | → Buy | Get Alert |
| 07/02/2021 | RNLX | Buy Now | Renalytix | — | — | Anita Dushyanth61% | → $38 | Initiates | → Buy | Get Alert |
| 04/09/2021 | BTAI | Buy Now | BioXcel Therapeutics | $2.04 | 3576.47% | Anita Dushyanth61% | → $1200 | Initiates | → Buy | Get Alert |
| 04/09/2021 | PCRX | Buy Now | Pacira BioSciences | $24.91 | 273.34% | Anita Dushyanth61% | → $93 | Initiates | → Buy | Get Alert |
